Medicare Coverage of Monoclonal Antibody Treatments for Alzheimer’s Disease: Key Issues from the CMS Proposed Coverage Decision

AD mAbs Key Issues CMS Draft Decision Memo Analysis Cover

Policy Brief

Medicare Coverage of Monoclonal Antibody Treatments for Alzheimer’s Disease: Key Issues from the CMS Proposed Coverage Decision

Overview

This Duke-Margolis issue brief summarizes the National Coverage Analysis (NCA) proposed decision memo issued by the Centers for Medicare & Medicaid Services (CMS) for the use of monoclonal antibodies (mAbs) to treat Alzheimer’s disease (AD). Our analysis focuses on key questions that would be valuable for CMS to clarify and that should be the subject of comments during the comment period that closes on February 10, 2022.

Duke-Margolis Authors

nitzan arad

Nitzan Arad, LLM

Assistant Research Director

beena

Beena Bhuiyan Khan, MSc

Research Director for Payment and Coverage Policy

Hannah Graunke Headshot

Hannah Graunke, MPP

Senior Policy Analyst

MHL

Marianne Hamilton Lopez, PhD, MPA

Senior Research Director, Biomedical Innovation
Faculty Director of the Duke-Margolis Postdoctoral Associates & Affiliated Fellows Program
Adjunct Associate Professor
Senior Team Member
Margolis Core Faculty

Mark McClellan

Mark McClellan, MD, PhD

Director of the Duke-Margolis Institute for Health Policy
Robert J. Margolis, MD, Professor of Business, Medicine and Policy
Margolis Executive Core Faculty